全文获取类型
收费全文 | 6361篇 |
免费 | 467篇 |
国内免费 | 5篇 |
出版年
2023年 | 39篇 |
2022年 | 34篇 |
2021年 | 138篇 |
2020年 | 86篇 |
2019年 | 111篇 |
2018年 | 146篇 |
2017年 | 114篇 |
2016年 | 209篇 |
2015年 | 335篇 |
2014年 | 400篇 |
2013年 | 414篇 |
2012年 | 574篇 |
2011年 | 475篇 |
2010年 | 339篇 |
2009年 | 268篇 |
2008年 | 338篇 |
2007年 | 380篇 |
2006年 | 284篇 |
2005年 | 324篇 |
2004年 | 286篇 |
2003年 | 247篇 |
2002年 | 222篇 |
2001年 | 59篇 |
2000年 | 38篇 |
1999年 | 56篇 |
1998年 | 80篇 |
1997年 | 54篇 |
1996年 | 51篇 |
1995年 | 53篇 |
1994年 | 36篇 |
1993年 | 36篇 |
1992年 | 33篇 |
1991年 | 26篇 |
1990年 | 24篇 |
1989年 | 23篇 |
1988年 | 25篇 |
1987年 | 27篇 |
1986年 | 20篇 |
1985年 | 25篇 |
1984年 | 31篇 |
1983年 | 14篇 |
1982年 | 28篇 |
1981年 | 20篇 |
1980年 | 14篇 |
1979年 | 16篇 |
1978年 | 17篇 |
1977年 | 22篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1974年 | 14篇 |
排序方式: 共有6833条查询结果,搜索用时 15 毫秒
141.
Le Roux Johannes J. Crous Pedro W. Kamutando Casper N. Richardson David M. Strasberg Dominique Wingfield Michael J. Wright Mark G. Valverde Angel 《Plant and Soil》2021,459(1-2):277-288
Plant and Soil - The hydrolysis of organic P in soils is a relevant aspect contributing to the supply P to plants, which is affected by adsorbent capacity and biological properties of soils. This... 相似文献
142.
143.
Daisylyn Senna Tan Yanpu Chen Ya Gao Anastasia Bednarz Yuanjie Wei Vikas Malik Derek Hoi-Hang Ho Mingxi Weng Sik Yin Ho Yogesh Srivastava Sergiy Velychko Xiaoxiao Yang Ligang Fan Johnny Kim Johannes Graumann Gary D. Stormo Thomas Braun Jian Yan Hans R. Schler Ralf Jauch 《Molecular biology and evolution》2021,38(7):2854
144.
145.
Mario Gimona Maria Felice Brizzi Andre Boon Hwa Choo Massimo Dominici Sean M. Davidson Johannes Grillari Dirk M. Hermann Andrew F. Hill Dominique de Kleijn Ruenn Chai Lai Charles P. Lai Rebecca Lim Marta Monguió-Tortajada Maurizio Muraca Takahiro Ochiya Luis A. Ortiz Wei Seong Toh Yong Weon Yi Sai Kiang Lim 《Cytotherapy》2021,23(5):373-380
Mesenchymal stromal/stem cells (MSCs) have been widely tested against many diseases, with more than 1000 registered clinical trials worldwide. Despite many setbacks, MSCs have been approved for the treatment of graft-versus-host disease and Crohn disease. However, it is increasingly clear that MSCs exert their therapeutic functions in a paracrine manner through the secretion of small extracellular vesicles (sEVs) of 50–200 nm in diameter. Unlike living cells that can persist long-term, sEVs are non-living and non-replicative and have a transient presence in the body. Their small size also renders sEV preparations highly amenable to sterilization by filtration. Together, acellular MSC-sEV preparations are potentially safer and easier to translate into the clinic than cellular MSC products. Nevertheless, there are inherent challenges in the development of MSC-sEV drug products. MSC-sEVs are products of living cells, and living cells are sensitive to changes in the external microenvironment. Consequently, quality control metrics to measure key identity and potency features of MSC-sEV preparations have to be specified during development of MSC-sEV therapeutics. The authors have previously described quantifiable assays to define the identity of MSC-sEVs. Here the authors discuss requirements for prospective potency assays to predict the therapeutic effectiveness of the drug substance in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Although potency assays should ideally reflect the mechanism of action (MoA), this is challenging because the MoA for the reported efficacy of MSC-sEV preparations against multiple diseases of diverse underlying pathology is likely to be complex and different for each disease and difficult to fully elucidate. Nevertheless, robust potency assays could be developed by identifying the EV attribute most relevant to the intended biological activity in EV-mediated therapy and quantifying the EV attribute. Specifically, the authors highlight challenges and mitigation measures to enhance the manufacture of consistent and reproducibly potent sEV preparations, to identify and select the appropriate EV attribute for potency assays despite a complex “work-in-progress” MoA and to develop assays likely to be compliant with regulatory guidance for assay validation. 相似文献
146.
147.
Lena-Maria Makowski Merle Leffers Johannes Waltenberger Evangelia Pardali 《Journal of cellular and molecular medicine》2021,25(11):5316-5325
Type 2 diabetes mellitus (T2DM) leads to monocyte dysfunction associated with atherogenesis and defective arteriogenesis. Transforming growth factor (TGF)-β1, placenta growth factor (PlGF)-1 and vascular endothelial growth factor (VEGF)A play important roles in atherogenesis and arteriogenesis. VEGF-receptor (VEGFR)-mediated monocyte migration is inhibited in T2DM (VEGFA resistance), while TGF-β1-induced monocyte migration is fully functional. Therefore, we hypothesize that TGF-β antagonises the VEGFA responses in human monocytes. We demonstrate that monocytes from T2DM patients have an increased migratory response towards low concentrations of TGF-β1, while PlGF-1/VEGFA responses are mitigated. Mechanistically, this is due to increased expression of type II TGF-β receptor in monocytes under high-glucose conditions and increased expression of soluble (s)VEGFR1, which is known to interfere with VEGFA signalling. VEGFA resistance in monocytes from T2DM patients can be rescued by either experimental down-regulation of TGF-β receptor expression in vitro or by functional blocking of TGF-β signalling using either a TGF-β receptor kinase inhibitor or a TGF-β neutralizing antibody. Our data demonstrate that both T2DM and high-glucose potentiate the TGF-β pathway. TGF-β signalling impairs VEGFR-mediated responses in T2DM monocytes and in this way contributes to mononuclear cell dysfunction, provide novel insights into T2DM vascular dysfunction. 相似文献
148.
Ljudmilla Borisjuk Thomas Neuberger J?rg Schwender Nicolas Heinzel Stephanie Sunderhaus Johannes Fuchs Jordan O. Hay Henning Tschiersch Hans-Peter Braun Peter Denolf Bart Lambert Peter M. Jakob Hardy Rolletschek 《The Plant cell》2013,25(5):1625-1640
Constrained to develop within the seed, the plant embryo must adapt its shape and size to fit the space available. Here, we demonstrate how this adjustment shapes metabolism of photosynthetic embryo. Noninvasive NMR-based imaging of the developing oilseed rape (Brassica napus) seed illustrates that, following embryo bending, gradients in lipid concentration became established. These were correlated with the local photosynthetic electron transport rate and the accumulation of storage products. Experimentally induced changes in embryo morphology and/or light supply altered these gradients and were accompanied by alterations in both proteome and metabolome. Tissue-specific metabolic models predicted that the outer cotyledon and hypocotyl/radicle generate the bulk of plastidic reductant/ATP via photosynthesis, while the inner cotyledon, being enclosed by the outer cotyledon, is forced to grow essentially heterotrophically. Under field-relevant high-light conditions, major contribution of the ribulose-1,5-bisphosphate carboxylase/oxygenase–bypass to seed storage metabolism is predicted for the outer cotyledon and the hypocotyl/radicle only. Differences between in vitro– versus in planta–grown embryos suggest that metabolic heterogeneity of embryo is not observable by in vitro approaches. We conclude that in vivo metabolic fluxes are locally regulated and connected to seed architecture, driving the embryo toward an efficient use of available light and space. 相似文献
149.
Nils Offen Johannes Flemming Hares Kamawal Ruhel Ahmad Wanja Wolber Christian Geis Holm Zaehres Hans R Sch?ler Hannelore Ehrenreich Albrecht M Müller Anna-Leena Sirén 《Molecular medicine (Cambridge, Mass.)》2013,19(1):399-408
Induced cell fate changes by reprogramming of somatic cells offers an efficient strategy to generate autologous pluripotent stem (iPS) cells from any adult cell type. The potential of iPS cells to differentiate into various cell types is well established, however the efficiency to produce functional neurons from iPS cells remains modest. Here, we generated panneural progenitor cells (pNPCs) from mouse iPS cells and investigated the effect of the neurotrophic growth factor erythropoietin (EPO) on their survival, proliferation and neurodifferentiation. Under neural differentiation conditions, iPS-derived pNPCs gave rise to microtubule-associated protein-2 positive neuronlike cells (34% to 43%) and platelet-derived growth factor receptor positive oligodendrocytelike cells (21% to 25%) while less than 1% of the cells expressed the astrocytic marker glial fibrillary acidic protein. Neuronlike cells generated action potentials and developed active presynaptic terminals. The pNPCs expressed EPO receptor (EPOR) mRNA and displayed functional EPOR signaling. In proliferating cultures, EPO (0.1–3 U/mL) slightly improved pNPC survival but reduced cell proliferation and neurosphere formation in a concentration-dependent manner. In differentiating cultures EPO facilitated neurodifferentiation as assessed by the increased number of β-III-tubulin positive neurons. Our results show that EPO inhibits iPS pNPC self-renewal and promotes neurogenesis. 相似文献
150.